Search
Desmethylprodine
go.drugbank.com/drugs/DB01478ExperimentalIllicitIt has been listed as a Schedule I controlled drug in the United States, and thus is not used clinically. It is known to be a designer drug, synthesized in 1977, for the purpose of recreational use.
Ramipril
go.drugbank.com/drugs/DB00178ApprovedInvestigationalRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of AC...
Macitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH). It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan in part due to its lower risk ...
TRGFT-201
go.drugbank.com/drugs/DB23064ApprovedInvestigationalisolated from an HLA-matched donor's mobilized peripheral blood — purified hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Tregs), and conventional T cells (Tcons) — administered as
Sulfacytine
go.drugbank.com/drugs/DB01298ApprovedSulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle.
CIGB 300
go.drugbank.com/drugs/DB16464InvestigationalCIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)
ATG002
go.drugbank.com/drugs/DB05068InvestigationalATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process.
ND1251
go.drugbank.com/drugs/DB05132ExperimentalND1251 may also have applications in other disorders, such as Alzheimer's disease, mild cognitive impairment, multiple sclerosis and certain respiratory diseases.
Anti-SARS-CoV-2 equine immunoglobulin fragments
go.drugbank.com/drugs/DB16368InvestigationalAnti-SARS-CoV-2 equine immunoglobulin fragments, also known as INOSARS, is a polyvalent passive immunization being tested in the clinical trial NCT04514302 (Safety and Efficacy of Anti-SARS-CoV-2 Equine
Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalIt antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.